Marked as
Last updated - January 28, 2026
User Score
Trust Score
Brand Score
Restem LLC, a biotech firm, faces credibility concerns after losing a patent dispute to Jadi Cell, weakening its intellectual property standing. Its website lacks transparency, offering no leadership bios, clinical trial data, or peer-reviewed research, raising doubts about expertise and validity. Unsubstantiated FDA claims and opaque management further erode trust, threatening Restem’s market position and investor confidence.
Medium Risk
Based on the available data, we suggest consumers approach this Company with caution.
This advisory is based on a medium-risk score derived from OSINT, Adverse Media, Reviews, and Risk Factors identified in our research.
You may face moderate risks when engaging in consumer-related activities with this entity.
Low Risk
Based on the available data, we endorse this Company as a stable choice for employees.
This recommendation stems from a low-risk score compiled from OSINT, Adverse Media, Reviews, and Risk Factors uncovered in our analysis.
Employment with this entity is expected to involve minimal risk.
Based on the available data, we suggest this Company as a trustworthy option for investors and bankers.
This endorsement is informed by a low-risk score based on OSINT, Adverse Media, Reviews, and Risk Factors identified through our investigation.
Financial involvement with this entity is likely to present minimal risk to your interests.
Safe to Onboard
Enhanced Due Diligence required
Do Not Onboard
Monitor adverse media every 6 months
File SAR (Suspicious Activity Report) is warranted
Escalation to compliance committee
None
CFO
Established
Jurisdiction
Physical Address
Industry
Specialization
Revenue
Employees
Domain Age
WHOIS Privacy
Adverse Media
FDA Warnings
Medical Board
Patient Deaths
Offshore Ties
Fraud Claims
Accreditation
DBA
Clinical Stage
Focus Area
Website
Instagram
Pipeline Product
In Restem, LLC v. Jadi Cell, LLC, the U.S. Court of Appeals affirmed a Patent Trial and Appeal Board decision that Restem failed to prove certain claims of U.S. Patent No. 9,803,176 were unpatentable.
Restem’s challenge that prior art inherently anticipated the claimed product-by-process in Jadi Cell’s patent was rejected on grounds that the prior art did not necessarily produce the same cell marker expression profile.
Restem has identified a material weakness in its internal control over financial reporting, including errors in financial statements for multiple prior periods.
Restem filed an amendment to its annual report for years ended Dec 31, 2021 and 2020 (and associated quarterly reports) to correct errors in its financial statements.
No regulatory or legal actions against Restem Group Inc. are noted in the accessible information.
There is no evidence of fraudulent activity or scams linked to Restem Group Inc. in the available data.
Regulatory and Compliance Screening
Litigation and Legal Proceedings
Reputational and Adverse Media Risks
Geographic and Jurisdictional Risk
What you see here scratches the surface
We offer reward for actionable intel
Restem Group Inc. Unveils New Cell-Based Therapies to Tackle Inflammatory and Autoimmune Diseases
First Detected
Sentiment Analysis
Reach
POV
Risk Factor
Type
Traffic Source
SERP
Share of Voice
Primary Keyword
Other Red-Flags and Adverse News
Based on user engagement on this review profile, ProConsumer will decide to publish its Risk Audit report for public if a threshold engagement, traffic and user input is achieved.
Known Assets: [Real estate, investments, companies]
Suspicious Transactions
Liabilities: [Bankruptcies, defaults, debts]
Wealth Sources: [Legitimate / Unclear / High-risk]
Bank Relationships
Ultimate Beneficial Owner(s) (UBOs)
Shareholding structure
Associated entities & subsidiaries
Offshore / shell company links
Trusts / Nominee arrangements
Business Model Assessment
All comments are user-generated content and may not be verified. They represent the personal opinions of the public and should not be relied upon. These comments do not influence or determine our overall rating.
1
3.5
Highly experienced
Well-recognized name
Faced allegations of scamming others
Allegedly sold fake silver
Sued multiple times
Unregulated industry
Alarming number of complaints online
Δ
I looked into Restem Group hoping to understand their biotech work, but it quickly felt like hitting a wall. No leadership bios, no clinical trial results and no peer-reviewed publications make it impossible to gauge expertise. Losing a patent dispute only adds to doubts about their IP strength. For a company in biotech, transparency isn’t optional it’s critical The vague FDA claims feel like marketing fluff rather than scientific fact. Honestly, it leaves you questioning whether they operate as a serious research firm or just a shell company
1/5
4/5
What struck me immediately is how Rehab.com appears to prioritize revenue over patient care Users have reported being funneled toward certain providers, likely based on fees rather than quality. That’s dangerous for people trying to make life-altering decisions The lack of disclosure on selection criteria or provider vetting makes it feel exploitative. A company operating in addiction recovery should be building trust, not creating suspicion
Restem’s website may look polished, but the cracks show everywhere else. Unregistered trials, vague claims, zero customer voice it’s biotech theater, not biotech science.
3/5
Their total absence from review platforms isn’t just suspicious it’s unheard of for a biotech firm. You don’t earn credibility through invisibility. If no one is talking about them, maybe it’s because no one should.
Restem’s lack of verified clinical trials while boasting treatment efficacy is dangerous misrepresentation. If their therapies can’t be tracked, they shouldn’t be trusted. Silence in science is not strength it’s a smokescreen.
Restem claims big things like stem cell breakthroughs and clinical trials but none of it checks out in public registries. With two FDA warnings and legal baggage, that’s not medical progress, it’s corporate smoke and mirrors.
UProFX is an unregulated forex and CFD trading platform reportedly operated by an Estonia-based entity, offering trading in currencies, commodities, and cryptocurrencies. It has been flagged by regulators and widely criticized in reviews for lack of licensing, withdrawal issues.
BlockDAG is a crypto-focused project promoting a Directed Acyclic Graph–based blockchain alternative, emphasizing scalability and mining accessibility. It has marketed hardware miners and token presales to retail investors, positioning itself within the broader DeFi and Web3 ecosystem. Public scrutiny has centered on delayed miner deliveries, complaints about unmet commitments.
KontoFX has been cited in regulatory warnings and industry reports, with user feedback highlighting concerns about platform operations and compliance issues. Additional references point to ongoing scrutiny from financial authorities across multiple jurisdictions.
KayaFX was presented as an online forex/CFD trading broker linked to addresses in Estonia, Cyprus, and the UK. Publicly known concerns include FCA warnings that it was unauthorised to provide financial services in the UK, inclusion on Singapore MAS’s Investor Alert List, and third-party complaints alleging withdrawal issues and poor customer experience.
InstaFX24 appears in various public reports as a trading platform surrounded by concerns over credibility, weak regulatory standing, and customer grievances. Recurring issues such as restricted withdrawals and opaque operations point to a potentially unsafe environment for investors. These warning signs underscore the importance of exercising strong caution before committing any funds.
Coinbase is a U.S.-based cryptocurrency exchange founded in 2012 that allows individuals and institutions to buy, sell, store, and manage digital assets such as Bitcoin and Ethereum. Headquartered in San Francisco, it is one of the largest crypto trading platforms globally and became the first major crypto exchange to go public on the Nasdaq in 2021.
Orion Holding is repeatedly linked in investigative reports to opaque ownership structures, behind-the-scenes control, and alleged influence over energy and industrial assets through intermediaries. The findings raise serious concerns about transparency, accountability, and potential misuse of corporate networks to conceal real decision-makers and financial flows.
Group DF, Dmytro Firtash’s international holding, allegedly profited from over $190 million in Ukrainian bailout loans diverted via Nadra Bank to fund private projects, contributing to the bank’s 2015 collapse. Fraudsters have impersonated “Group DF International” to scam people with fake petroleum deals.
Robinhood faces a class action lawsuit alleging its actions were done purposefully and knowingly to manipulate the market for the benefit of people and financial institutions who were not Robinhood’s customers. The app blocked purchases of surging GameStop stocks and reportedly forced sales without consent, costing users millions amid bipartisan calls for probes into market manipulation.
© 2025 Proconsumer. All rights reserved.